Poster Abstracts • OFID 2018:5 (Suppl 1) • S329 bowel movements per day for one or more days with 7 diarrhea-free days between episodes. Diarrheal illnesses were identified through longitudinal household-based weekly symptom surveillance. The c 2 test, two-sample t-test, and log-binomial regression were performed to evaluate baseline characteristics and the association between diarrhea during pregnancy and adverse birth outcomes.
Session: 133. Enteric Infections
Background. Patients with pyogenic vertebral osteomyelitis (PVO) are expected to have increased risk of bone loss. Therefore, early bisphosphonate therapy would be clinically effective for PVO patients with osteoporosis.
Methods. A retrospective case review was performed on PVO patients with osteoporosis. PVO patients were divided into three groups: group A (initiation of bisphosphonate within 6 weeks after PVO diagnosis); group B (initiation of bisphosphonate between 6 weeks and 3 months after PVO diagnosis), and group C (no treatment for osteoporosis). Cox proportional hazard model was used to evaluate long-term effectiveness and safety of bisphosphonate in PVO patients, and event of interests included surgical treatment, recurrence of infection, subsequent fracture of adjacent vertebral bodies, and death.
Results. A total of 360 PVO patients with osteoporosis were investigated for the four events of interest. Group A PVO patients had significantly lower hazard ratios for undergoing later (more than 6 weeks after diagnosis) surgery than group C PVO patients (P = 0.014 for model 1 and 2) (Figure 1 ) despite similar occurrences of overall surgery. Significant difference was also observed in the occurrence of subsequent fractures at adjacent vertebral bodies (P = 0.001 for model 1 and P = 0.002 for model 2), and group A and B PVO patients had significantly lower hazard ratios for subsequent fracture than group C PVO patients (Figure 2 ). There were no significant differences in the hazard ratios of recurrence and death among the three groups.
Conclusion. Early bisphosphonate treatment in PVO patients with osteoporosis was associated with significantly lower occurrence of subsequent vertebral fracture at adjacent vertebral bodies, and lower occurrence of later surgery. Background. Shiga toxin-producing Escherichia coli (STEC) is associated with potentially life-threatening dysentery, along with its most feared complication, the hemolytic-uremic syndrome (HUS), occurring in up to 20% of STEC-infected patients. 10-30% of patients may experience chronic renovascular and neurologic sequelae after acute resolution. We describe clinical features and outcomes of a young, male military recruit population hospitalized for STEC infection and HUS in 2017.
Clinical Features and Outcomes of United States Marine Corps Recruits
Methods. Between October and November 2017, an STEC outbreak occurred at Marine Corps Recruit Depot San Diego (MCRD-SD) affecting 244 recruits, including 30 who required hospitalization. Polymerase chain reaction and pulsed-field gel electrophoresis of stool culture isolates demonstrated stx2-positive E. coli O157:H7. Thirty recruits required hospitalization; the remaining 214 underwent daily clinical evaluation and laboratory testing at MCRD with daily crystalloid volume expansion until the resolution of dysentery.
Results. 50% (15/30) of hospitalized recruits developed HUS and were initially managed with volume expansion until the onset of oliguria. Five recruits with severe HUS required hemodialysis; six required intensive critical care unit (ICU) admission; and three suffered from respiratory failure requiring mechanical ventilation. Average length of hospitalization was 10 days. Patients requiring hemodialysis received an average 7.4 days of renal replacement. Three patients experienced encephalopathy with seizures and were managed with levetiracetam and corticosteroids for Stx-induced cerebral edema. One patient received eculizumab, a terminal complement inhibitor approved for atypical HUS, with resolution of seizures and return to his neurocognitive baseline but with persistent electroencephalographic abnormalities. There were no deaths, and all recruits had recovery of renal function.
Conclusion. This case series represents the largest STEC-HUS outbreak affecting a military population. Rates of HUS and mortality were lower than seen in prior outbreaks, in part due to a high level of baseline health and early detection and management of suspect cases. Early volume expansion and close monitoring of cases may have reduced the risk for HUS progression and long-term renal sequelae.
Disclosures. Background. Acute gastroenteritis (AGE) is a major cause of office and emergency department (ED) visits in the United States. Most patients can be managed with supportive care alone, although some require antibiotics. Limiting unnecessary antibiotic use can minimize side effects and the development of resistance. We used national data to assess antibiotic prescribing for AGE to target areas for stewardship efforts.
Methods. We used the 2006-2015 National Hospital Ambulatory Medical Care Survey of EDs and National Ambulatory Medical Care Survey to describe antibiotic prescribing for AGE. An AGE visit was defined as one with a new problem (<3 months) as the main visit indication and an ICD-9 code for bacterial or viral gastrointestinal infection or AGE symptoms (nausea, vomiting, and/or diarrhea). We excluded visits with ICD-9 codes for Clostridium difficile or an infection usually requiring antibiotics (e.g., pneumonia). We calculated national annual percentage estimates based on weights of sampled visits and used an α level of 0.01, recommended for these data.
Results. Of the 12,191 sampled AGE visits, 13% (99% CI: 11-15%) resulted in antibiotic prescriptions, equating to an estimated 1.3 million AGE visits with antibiotic prescriptions annually. Antibiotics were more likely to be prescribed in office AGE visits (16%, 99% CI: 12-20%) compared with ED AGE visits (11%, 99% CI: 9-12%; P < 0.01). Among AGE visits with antibiotic prescriptions, the most frequently prescribed were fluoroquinolones (29%, 99% CI: 21-36%), metronidazole (18%, 99% CI: 13-24%), and penicillins (18%, 99% CI: 11-24%). Antibiotics were prescribed for 25% (99% CI: 8-42%) of visits for bacterial AGE, 16% (99% CI: 12-21%) for diarrhea without nausea or vomiting, and 11% (99% CI: 8-15%) for nausea, vomiting, or both without diarrhea. Among AGE visits with fever (T ≥ 100.9 o F) at the visit, 21% (99% CI: 11-31%) resulted in antibiotic prescriptions.
Conclusion. Patients treated for AGE in office settings were significantly more likely to receive prescriptions for antibiotics compared with those seen in an ED, despite likely lower acuity. Antibiotic prescribing was also high for visits for nausea or vomiting, conditions that usually do not require antibiotics. Antimicrobial stewardship for AGE is needed, especially in office settings.
Disclosures. All authors: No reported disclosures. Background. Biofire FilmArray multiplexed nucleic acid amplification tests (NAAT) for bacterial diarrhea include probes specific for EPEC. However, the platform does not differentiate typical EPEC (tEPEC, defined as carrying eaeA and bfp) which have strong epidemiologic associations with diarrhea from atypical EPEC (aEPEC, carrying eaeA but not bfp) for which there is a weaker association. Nevertheless, emerging data suggest that aEPEC subsets carrying efa1/lifA which encodes for adherence factor 1/lymphocyte inhibitory factor A, are associated with diarrhea. The role of EPEC and its subtypes as agents of bacterial diarrhea have not been well defined in immunosuppressed and cancer patients.
Characterization of Enteropathogenic Escherichia coli (EPEC) in Cancer
Methods. We characterized EPEC subtypes in stools from healthy individuals with no diarrhea (HI, N = 21), cancer patients with diarrhea and negative NAAT (DN, N = 25) and patients with diarrhea positive NAAT for EPEC (DP, N = 54). EPEC isolated from stool cultures were tested for eaeA and bfp, stx and other E. coli pathotypes. We estimated the number of fecal EPEC using a qPCR for eaeA, efa1/lifA that detected 5.6 × 10 1 to 5 × 10 7 cfu/mg of stool. Results. Demographic characteristics and underlying malignancy were similar between DN and DP groups. DP were more likely to have diarrhea on admission than DN [46/52 (88%) vs. 13/25 (52%), P < 0.01]. Stool cultures confirmed EPEC in 24/52 (60%) DP of which 23/24 (96%) were aEPEC. Fecal qPCR for eaeA confirmed EPEC in 43/52 (83%) of DP, 0/25 DN and in 3/21 (14%) of HI (P < 0.001). DP excreted a higher number of EPEC cfu/mg of stool than HI (median 168 vs. 1.18 cfu/mg, P < 0.001) and only DP excreted EPEC efa1/lifA (+) [14/52 DP (27%) vs. 0/25 DN and 0/21 HI; P < 0.001]. When compared with DP EPEC efa1/lifA (-), DP EPEC efa1/lifA (+) had a longer median duration of illness (3 days vs. 1 days, P < 0.05); more likely to be hematopoietic stem cell transplant recipients [7/14 (50%) 
